36 completed, 19 unknown, 17 recruiting, 10 terminated. 94 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 94 | Completed 36, Unknown 19, Recruiting 17, Terminated 10, Not yet recruiting 6, Withdrawn 3, Enrolling by invitation 2, Active not recruiting 1 |
Follow Skin Diseases, Vascular: new trials by email Literature Review of Skin Diseases, Vascular trials Research Report on Skin Diseases, Vascular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) KVD900 600 mg - Hereditary Angioedema | Phase 4 | Recruiting | KalVista Pharmaceuticals, Ltd. | 100 | 2026-08-17 | 2026-09-17 |
| Non Inferiority KawasakI Trial With Anakinra Anakinra, Intravenous Immunoglobulins, Human - Kawasaki Disease, Anakinra | Phase 4 | Withdrawn | Meyer Children's Hospital IRCCS | 2026-04-01 | 2026-10-26 | |
| Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis Vanakizumab, Ivarmacitinib, Prednisone - Takayasu Arteritis (TAK) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 180 | 2026-04-01 | 2026-03-05 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Rituximab - ANCA Associated Vasculitis (AAV), Polyangiitis (GPA) | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2026-02-01 | 2026-03-05 |
| Effect of Pirfenidone on TA Fibrosis Pirfenidone Capsules, Placebo - Takayasu Arteritis | Phase 4 | Not yet recruiting | Shanghai Zhongshan Hospital | 92 | 2025-12-20 | 2026-01-08 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Open Label Treprostinil Raynaud's Study Oral treprostinil (UT-15C) sustained release tablets - Raynaud's Disease, Raynaud Phenomena | Phase 4 | Recruiting | Brigham and Women's Hospital | 30 | 2025-10-15 | 2026-03-24 |
| SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis Gliflozin - Lupus Nephritis (LN), ANCA Associated Vasculitis (AAV) | Phase 4 | Not yet recruiting | Federico II University | 40 | 2025-09-01 | 2025-06-25 |
| The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis Deucravacitinib, Adalimumab - Takayasu Arteritis (TAK) | Phase 4 | Not yet recruiting | Chinese SLE Treatment And Research Group | 50 | 2025-06-15 | 2025-06-10 |
| Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin - Kawasaki Disease, Coronary Artery Aneurysm | Phase 4 | Recruiting | Children's Hospital of Fudan University | 100 | 2025-06-01 | 2026-07-06 |
| Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Garadacimab - Hereditary Angioedema | Phase 4 | Completed | CSL Behring | 18 | 2025-04-28 | 2026-07-23 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Shingrix, vaccination with 2 doses of Shingrix vaccine - Systemic Vasculitis, Spondylarthropathies | Phase 4 | Enrolling by invitation | Region Skane | 240 | 2024-12-17 | 2025-01-10 |
| Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis Avacopan, prednisolone and rituximab, Prednisolone and rituximab - ANCA Associated Vasculitis (AAV) | Phase 4 | Recruiting | Chiba University | 160 | 2024-11-15 | 2025-05-04 |
| A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE) | Phase 4 | Completed | Nang Kuang Pharmaceutical Co., Ltd. | 5 | 2024-09-27 | 2025-12-18 |
| A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis Prednisone, Methotrexate, Tocilizumab - Takayasu Arteritis | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 124 | 2024-06-28 | 2024-10-17 |
| Lanadelumab in Long-term Prophylaxis of Acquired Angioedema Lanadelumab 300 mg - Angioedema | Phase 4 | Recruiting | Bernstein Clinical Research Center | 5 | 2024-06-01 | 2025-02-25 |
| Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU) human histaglobulin, placebo, Loratadine 10 Mg - Chronic Spontaneous Urticaria | Phase 4 | Unknown | Hangzhou Grand Biologic Pharmaceutical, Inc. | 252 | 2024-03-31 | 2024-02-09 |
Showing 20 of 94. Sign in to see all of them.
Urticaria (16) · Chronic Urticaria (14) · Granulomatosis with Polyangiitis (13) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (11) · Angioedemas, Hereditary (10) · Microscopic Polyangiitis (10) · Takayasu Arteritis (9) · Giant Cell Arteritis (6) · Raynaud Disease (6) · Mucocutaneous Lymph Node Syndrome (5) · Vasculitis (5) · Angioedema (4) · Behcet Syndrome (4) · Churg-Strauss Syndrome (4) · Arthritis, Juvenile (3)
Skin Diseases (94) · Skin and Connective Tissue Diseases (94) · Immune System Diseases (72) · Cardiovascular Diseases (68) · Vascular Diseases (68) · Hypersensitivity (43) · Vasculitis (43) · Hypersensitivity, Immediate (41) · Autoimmune Diseases (31) · Urticaria (24) · Pathologic Processes (21) · Pathological Conditions, Signs and Symptoms (21) · Systemic Vasculitis (21) · Respiratory Tract Diseases (19)
desloratadine (9) · Omalizumab (8) · Rituximab (8) · Prednisone (6) · Azathioprine (5) · Glucocorticoids (5) · Methotrexate (5) · levocetirizine (5) · tofacitinib (5) · Adalimumab (4) · Complement C1 Inhibitor Protein (4) · Cyclophosphamide (4) · tocilizumab (4) · Cetirizine (3) · Prednisolone (3)
Shanghai Zhongshan Hospital (6) · Chinese SLE Treatment And Research Group (5) · Organon and Co (5) · Massachusetts General Hospital (4) · Assistance Publique - Hôpitaux de Paris (3) · Bernstein Clinical Research Center (2) · CSL Behring (2) · Charite University, Berlin, Germany (2) · Chiba University (2) · Children's Hospital of Fudan University (2) · Green Cross Corporation (2) · Hospices Civils de Lyon (2) · Otsuka America Pharmaceutical (2) · University of Colorado, Denver (2) · University of Sao Paulo General Hospital (2)
United States (28) · China (15) · France (7) · Germany (5) · Denmark (4) · Italy (4) · India (3) · Romania (3) · South Korea (3) · United Kingdom (3) · Brazil (2) · Bulgaria (2) · Hungary (2) · Japan (2) · Netherlands (2)
Lindi Jiang, PhD (4) · Fang Liu, MD (2) · Jonathan Bernstein, MD (2) · Marcus Maurer, MD (2) · Aaron B Waxman, MD, PhD (1) · Aleena Banerji, M.D. (1) · Alison Smith, MD, PhD (1) · Ana D Fernandes, MA (1)
PMID 25153486, PMID 34061144, PMID 14558057, PMID 18240234, PMID 19054820, PMID 19133920, PMID 21626222, PMID 22674883, PMID 23045170, PMID 23147964, PMID 23590801, PMID 25693055, PMID 25697557, PMID 27140403, PMID 27242368, PMID 27326985, PMID 27788880, PMID 28709817, PMID 29247107, PMID 29503044, PMID 29671921, PMID 30146446, PMID 31034999, PMID 31109849, PMID 33164993, PMID 33596356, PMID 33713769, PMID 33737935, PMID 34303860, PMID 35110332, PMID 35110333, PMID 35365179, PMID 35914662, PMID 36853224, PMID 36927642, PMID 37024906, PMID 37540159, PMID 37734880, PMID 38123922, PMID 38251564, PMID 39762098, PMID 41638742, PMID 41679320, PMID 41932224, PMID 42261247, PMID 42276802, PMID 42294825, PMID 42843284, PMID 9041949
2008 (2), 2009 (1), 2015 (1), 2018 (1), 2023 (1), 2025 (1), R01AI116658 (1)